Avinger (AVGR) Earns Daily News Impact Rating of -0.07

News stories about Avinger (NASDAQ:AVGR) have trended somewhat negative on Wednesday, according to Accern Sentiment. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Avinger earned a media sentiment score of -0.07 on Accern’s scale. Accern also assigned press coverage about the medical device company an impact score of 43.5824294053141 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Separately, Zacks Investment Research lowered shares of Avinger from a “buy” rating to a “hold” rating in a report on Monday, June 19th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Avinger has an average rating of “Hold” and a consensus price target of $3.50.

Shares of Avinger (NASDAQ:AVGR) traded down 2.8056% during midday trading on Wednesday, hitting $0.2425. 241,015 shares of the company were exchanged. The stock’s market capitalization is $5.80 million. The company has a 50-day moving average price of $0.27 and a 200-day moving average price of $0.27. Avinger has a 52-week low of $0.22 and a 52-week high of $5.15.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/09/20/avinger-avgr-earns-daily-news-impact-rating-of-0-07.html.

Avinger Company Profile

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.

Insider Buying and Selling by Quarter for Avinger (NASDAQ:AVGR)

Receive News & Ratings for Avinger Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply